Dr. Gettinger's primary translational research interests include understanding mechanisms of acquired resistance to targeted therapies, and developing biomarkers predictive of response to immunotherapies that target the programmed death receptor 1 (PD1) pathway.
Carcinoma, Non-Small-Cell Lung; Immunotherapy; Lung; Medical Oncology; Thoracic Neoplasms; Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Translational Research, Biomedical